BIOMAT Database Logo BIOMAT Database Logo

T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia. 1996

M Nakagawa, and D P Stites, and S Farhat, and A Judd, and A B Moscicki, and A J Canchola, and J F Hilton, and J M Palefsky
Department of Laboratory Medicine, School of Medicine, University of California at San Francisco 94143-0134, USA.

The incidence of human papillomavirus (HPV)-related cervical intraepithelial neoplasia (CIN) and cervical cancer is increased with immunodeficiency, but the role of immune response, including cell-mediated immunity, in disease prevention is not well understood. In this study, T-cell proliferative responses to six synthetic peptides with predicted immunogenic determinants from the HPV-16 E4, E6, E7, and L1 open reading frames were analyzed in 22 sexually active women with new-onset CIN and 65 sexually active women without cervical disease, characterized by cytology, colposcopy, and HPV testing. T-cell proliferative responses were demonstrated to all six HPV-16 peptides. Although not statistically significant, rates of reactivity to E6 (24-45) were higher among sexually active women without disease (26%) than among women with current CIN (7%), as was the overall number of peptides stimulating a response. Women with CIN may not respond to selected HPV antigens as well as women without disease do.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009856 Oncogene Proteins, Viral Products of viral oncogenes, most commonly retroviral oncogenes. They usually have transforming and often protein kinase activities. Viral Oncogene Proteins,Viral Transforming Proteins,v-onc Proteins,Transforming Proteins, Viral,v onc Proteins
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002578 Uterine Cervical Dysplasia Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE. Cervical Dysplasia,Cervical Intraepithelial Neoplasia,Cervix Dysplasia,Dysplasia of Cervix Uteri,Neoplasia, Cervical Intraepithelial,Cervical Intraepithelial Neoplasia, Grade III,Cervical Intraepithelial Neoplasms,Intraepithelial Neoplasia, Cervical,Cervical Dysplasia, Uterine,Cervical Dysplasias,Cervical Intraepithelial Neoplasm,Cervix Uteri Dysplasia,Cervix Uteri Dysplasias,Dysplasia, Cervical,Dysplasia, Cervix,Dysplasia, Uterine Cervical,Intraepithelial Neoplasm, Cervical,Intraepithelial Neoplasms, Cervical,Neoplasm, Cervical Intraepithelial,Neoplasms, Cervical Intraepithelial
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Nakagawa, and D P Stites, and S Farhat, and A Judd, and A B Moscicki, and A J Canchola, and J F Hilton, and J M Palefsky
Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia.
April 1996, The Journal of general virology,
M Nakagawa, and D P Stites, and S Farhat, and A Judd, and A B Moscicki, and A J Canchola, and J F Hilton, and J M Palefsky
Relationship of human papillomavirus type to grade of cervical intraepithelial neoplasia.
May 1992, JAMA,
M Nakagawa, and D P Stites, and S Farhat, and A Judd, and A B Moscicki, and A J Canchola, and J F Hilton, and J M Palefsky
Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.
December 2006, Immunology,
M Nakagawa, and D P Stites, and S Farhat, and A Judd, and A B Moscicki, and A J Canchola, and J F Hilton, and J M Palefsky
Human papillomavirus type 16 in vulvar carcinoma, vulvar intraepithelial neoplasia, and associated cervical neoplasia.
July 1991, Gynecologic oncology,
M Nakagawa, and D P Stites, and S Farhat, and A Judd, and A B Moscicki, and A J Canchola, and J F Hilton, and J M Palefsky
Relationship between human papillomavirus type 16 in the cervix and intraepithelial neoplasia.
January 1999, Obstetrics and gynecology,
M Nakagawa, and D P Stites, and S Farhat, and A Judd, and A B Moscicki, and A J Canchola, and J F Hilton, and J M Palefsky
Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia.
September 1999, The Journal of general virology,
M Nakagawa, and D P Stites, and S Farhat, and A Judd, and A B Moscicki, and A J Canchola, and J F Hilton, and J M Palefsky
T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
September 1996, The Journal of general virology,
M Nakagawa, and D P Stites, and S Farhat, and A Judd, and A B Moscicki, and A J Canchola, and J F Hilton, and J M Palefsky
Serologic response to human papillomavirus 16 among Australian women with high-grade cervical intraepithelial neoplasia.
January 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
M Nakagawa, and D P Stites, and S Farhat, and A Judd, and A B Moscicki, and A J Canchola, and J F Hilton, and J M Palefsky
[Human papillomavirus type 16- associated primary squamous cell carcinoma of the rectum following cervical intraepithelial neoplasia].
February 2011, Medicina clinica,
M Nakagawa, and D P Stites, and S Farhat, and A Judd, and A B Moscicki, and A J Canchola, and J F Hilton, and J M Palefsky
T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
June 2011, Journal of medical virology,
Copied contents to your clipboard!